| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 21 Jan 2026 | 12 Jan 2026 |
| Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/01/2026 ,inter alia, to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended 31 December 2025. Further, in accordance with the Companys Code of Conduct for Prohibition of Insider Trading, the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 January 2026 till the expiry of 48 hours from the date the said financial results are made public Enclosed (As Per BSE Announcement Dated on: 21/01/2026) | ||
| Board Meeting | 31 Oct 2025 | 17 Oct 2025 |
| Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2025 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended 30 September 2025. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 October 2025 till the expiry of 48 hours from the date the said financial results are made public. Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September 2025 (As per BSE Announcement dated on: 31.10.2025) | ||
| Board Meeting | 24 Jul 2025 | 17 Jul 2025 |
| Tatva Chintan Pharma Chem Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/07/2025 inter alia to consider and approve and take on record the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30 June 2025. Further in accordance with the Companys Code of Conduct for Prohibition of Insider Trading the Company has intimated its designated persons regarding the closure of the Trading Window for trading in the Companys equity shares from 01 July 2025 till the expiry of 48 hours from the date the said financial results are made public. Enclosed (As per BSE Announcement Dated on 24/07/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, PMS SEBI Regn. No: INP000002213, IA SEBI Regn. No: INA000000623, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
